TGA Peptide Scheduling Changes: What Changed in 2025-2026

Overview of Recent Changes

The Therapeutic Goods Administration (TGA) has made several significant changes to peptide scheduling and regulation between mid-2025 and early 2026. These changes reflect a tightening regulatory environment driven by safety concerns, grey market activity, and alignment with international standards.

This post covers the three most impactful changes practitioners and consumers need to understand.

Melanotan II - Schedule 9 Reclassification

The reclassification of Melanotan II from Schedule 4 (Prescription Only) to Schedule 9 (Prohibited) was the most high-profile change in this period. Key details include:

1. The reclassification took effect on 1 October 2024 following an interim decision earlier that year
2. Melanotan II can no longer be legally prescribed, compounded, or supplied in Australia
3. Possession without authorisation is now a criminal offence in most jurisdictions
4. Only approved research institutions with specific permits can handle the substance

Why It Happened

The TGA cited multiple safety concerns including uncontrolled melanogenesis, cardiovascular risks, and the high prevalence of unregulated supply. Reports of adverse events linked to grey market Melanotan II products were a significant factor in the decision.

BPC-157 and the FDA Category 1 List

BPC-157 (Body Protection Compound-157) was placed on the US FDA's Category 1 list of bulk drug substances that cannot be compounded under Section 503A or 503B. While this is a US regulatory action, it has direct implications for Australian supply:

1. Many Australian compounding pharmacies source active pharmaceutical ingredients (APIs) from US-based suppliers
2. Reduced US manufacturing has tightened global API availability
3. Australian compounders must now source BPC-157 from alternative qualified suppliers
4. The TGA has signalled it is monitoring the situation closely

Current Status in Australia

BPC-157 remains Schedule 4 in Australia and can still be legally prescribed and compounded. However, practitioners should be aware of potential supply chain disruptions and verify their pharmacy's sourcing.

Compounding Framework Changes

The TGA has also updated the broader compounding regulatory framework affecting peptide access:

1. Increased GMP expectations - Compounding pharmacies producing sterile injectables face stricter good manufacturing practice requirements
2. Batch testing requirements - New guidance on identity and potency testing for compounded peptide products
3. Advertising restrictions - Tighter enforcement against clinics advertising specific peptide products to consumers
4. Prescriber oversight - Renewed emphasis on the requirement for genuine practitioner-patient relationships before prescribing

What This Means for Consumers

These changes collectively push the peptide landscape further toward legitimate medical pathways. Consumers seeking peptide therapies should:

1. Verify their prescriber is AHPRA-registered
2. Confirm their pharmacy holds appropriate TGA licences
3. Check the current scheduling status of any peptide before assuming availability
4. Be cautious of providers who seem unaware of recent regulatory changes

The Peptide Register database is updated regularly to reflect these scheduling changes.